Reduction of plasma angiotensin II to normal levels by antisense oligodeoxynucleotides against liver angiotensinogen cannot completely attenuate vascular remodeling in spontaneously hypertensive rats

Journal of Hypertension

Volumn 18, Issue 6, 2000, Pages 725-731

  Sugano, Masahiro ^a   Tsuchida, Keiko ^a   Sawada, Shojiro ^a   Makino, Naoki ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Angiotensin II; Angiotensinogen; Antisense oligodeoxynucleotides; Collagen; Spontaneously hypertensive rats; Vascular hypertrophy

Indexed keywords

ANGIOTENSIN; ANGIOTENSINOGEN; ANTISENSE OLIGODEOXYNUCLEOTIDE; ASIALOGLYCOPROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; MESSENGER RNA; RECEPTOR SUBTYPE;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HYPERTENSION; LIVER; MALE; MUSCLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; VASCULAR SMOOTH MUSCLE;

EID: 0034081912     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200018060-00010     Document Type: Article

References (42)

1. 1 Paquet JL, Bandomin-Legros M, Brunelle G, Meyer P. Angiotensin II-induoed proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens 1990; 8:565-572.
2. 2 Geistefer AAT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy but not hyperplasia of rat aortic smooth muscle cells. Circ Res 1990; 62:749-756.
3. 3 Kato H, Suzuki H, Tajima S, Ogata Y, Tominaga T, Sato A, et al. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens 1991; 9:17-22.
4. 4 Johnson CI. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension 1994; 23:258-268.
5. 5 Levy BI, Michel JB, Salzmann JL, Azizi M, Poitevin P, Safer M, et al. Effects of chronic inhibition of converting enzyme on mechanical and structural properties of arteries in rat renovascular hypertension. Circ Res 1988; 63:227-239.
6. 6 Jalil JE, Doering CW, Janicki JS, Pick R, Shroff S, Weber KT. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 1989; 64:1041-1050.
7. 7 Keeley FW, Elmoselhi A, Leenen FHH. Enalapril supresses normal accumulation of elastin and collagen in cardiovascular tissues of growing rats. Am J Physiol 1992; 262:H1013-H1021.
8. 8 Powell JS, Clozel JP, Muller RKM, Kuhn H, Hefti F, Hosang M, et al. Inhibitor of angiotensin converting enzyme prevents myointimal proliferation after vascular injury. Science 1989; 245:186-188.
9. 9 Gohlke P, Linz W, Scholkens BA, Wiemer G, Unger T. Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1996; 28: 397-402.
10. 10 Yoshida H, Kakuchi J, Guo DF, Furuta H, Iwai N, Jong R, et al. Analysis of the evolution of angiotensin II type 1 receptor gene in mammals (mouse, rat, bovine and human). Biochem Biophys Res Commun 1992; 186:1042-1049.
11. 11 de Gasparo M, Husain A, Alexander W, Catt KJ, Chiu AT, Frew M, et al. Proposed update of angiotensin receptor nomenclature. Hypertension 1995; 25:924-927.
12. 12 Levy BI, Benessiano J, Henrion D, Caputo L, Heymes C, Duriez M, et al. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 1996; 98:418-425.
13. 13 Benetos A, Lacolley P, Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997; 17:1152-1156.
14. 14 Otsuka S, Sugano M, Makino N, Sawada S, Hata T, Niho Y. Interaction of mRNAs for angiotensin II type 1 and type 2 receptors to vascular remodeling in spontaneously hypertensive rats. Hypertension 1998; 32:467-472.
15. 15 Jeunemaitre X, Soubrier F, Kotelevetsev YV, Lifton RP, Williams CS, Charru A, et al. Molecular basis of human hypertension: role of angiotensinogen. Cell 1992; 71:169-180.
16. 16 Caulfield M, Lavender P, Farrall M, Munroe P, Lawson M, Turner P, et al. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 1994; 330:1629-1633.
17. 17 Lynch KR, Peach MJ. Molecular biology of angiotensinogen. Hypertension 1991; 17:263-269.
18. 18 Makino N, Sugano M, Ohtsuka S, Sawada S. Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases both the blood pressure and plasma angiotensin II levels. Hypertension 1998; 31:1166-1170.
19. 19 Hayakari M, Kondoh Y, Ihumi H. A rapid and simple spectrophotometric assay of angiotensin-converting enzyme. Anal Biochem 1978; 84:361-369.
20. 20 Sugano M, Makino N, Yanaga T. The effects of renin-angiotensin system inhibition on aortic cholesterol content in cholesterol-fed rabbits. Atherosclerosis 1996; 127:123-129.
21. 21 Makino N, Sugano M, Otsuka S, Hata T. Molecular mechanism of angiotensin II type I and type II receptors in cardiac hypertrophy of spontaneously hypertensive rats. Hypertension 1997; 30:796-802.
22. 22 Terada Y, Tomita K, Nonoguchl H, Marumo F. PCR localization of angiotensin II receptor and angiotensinogen mRNA in rat kidney. Kidney Int 1993; 43:1251-1259.
23. 23 Koike G, Krieger JE, Jacob HJ, Mukoyama M, Pratt RE, Dzau VJ. Angiotensin converting enzyme and genetic hypertension: cloning of rat cDNA and characterization of the enzyme. Biochem Biophys Res Commun 1994; 198:380-386.
24. 24 Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encording the vascular type-1 angiotensin II receptor. Nature 1991; 351:233-236.
25. 25 Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95:651-653.
26. 26 Fort PH, Marty I, Piechaczyk M, Sabrouty SEI, Dani CH, Jeanteur PH, et al. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acid Res 1985; 13:1431-1442.
27. 27 Wu GY, Wilson JM, Shalaby F, Grossman M, Shafritz DA, Wu CH. Receptor-mediated gene delivery in vivo. J Biol Chem 1991; 266:14338-14342.
28. 28 Lu XM, Fischman AJ, Jyawook SL, Hendricks K, Tompkins RG, Yarmush ML. Antisense DNA delivery in vivo: liver targeting by receptor-mediated uptake. J Nucl Med 1994; 35:269-275.
29. 29 Kim HS, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, Best CF, et al. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA 1995; 92:2735-2739.
30. 30 Caulfield M, Lavender P, Newell-Price J, Farrall M, Kamdar S, Daniel H, et al. Linkage of the angiotensinogen gene locus to human essential hypertension in African Caribbeans. J Clin Invest 1995; 96:687-692.
31. 31 Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH. The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest 1995; 95:948-953.
32. 32 Brand E, Chatelain N, Keavney B, Caulfield M, Citterio L, Connell J, et al. Evaluation of the angiotensinogen locus in human essential hypertension: a European study. Hypertension 1998; 31:725-729.
33. 33 Nui T, Xu X, Rogus J, Zhou Y, Chen C, Yang J, et al. Angiotensinogen gene and hypertension in Chinese. J Clin Invest 1998; 101:188-194.
34. 34 Lodwick D, Kaiser MA, Harris J, Cumin F, Vincent M, Samani NJ. Analysis of the role of angiotensinogen in spontaneous hypertension. Hypertension 1995; 25:1245-1251.
35. 35 Sabri A, Levy BI, Poitevin P, Caputo L, Faggin E, Marotte F, et al. Differential roles of AT1 and AT2 receptor subtypes in vascular trophic and phenotypic changes in response to stimulation with angiotensin II. Arterioscler Thromb Vasc Biol 1997; 17:257-264.
36. 36 Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, et al. Angiotensin II type I receptor antagonist inhibits the gene expression of transforming growth factor-beta 1 and extracellular matrix in cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther 1995; 273:509-515.
37. 37 Benetos A, Safar ME. Aortic collagen, aortic stiffnes and AT1 receptors in experimental and human hypertension. Can J Physiol Pharmacol 1996; 94:862-866.
38. 38 Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine B, LeJemtel T, et al. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993; 88:1602-1609.
39. 39 Tomita N, Morishita R, Higaki J, Aoki M, Nakamura Y, Mikami H, et al. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen. Hypertension 1995; 26:131-136.
40. 40 Wielbo D, Serina C, Gyurko R, Phillips MI. Antisense inhibition of hypertension in the spontaneously hypertensive rat. Hypertension 1995; 25:314-319.
41. 41 Wielbo D, Simon A, Phillips MI, Toffolo S. Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides. Hypertension 1996; 28:147-151.
42. 42 Tanimoto K, Sugiyama F, Goto Y, Ishida J, Takimoto E, Yagami K, et al. Angiotensinogen-deficient mice with hypotension. J Biol Chem 1994; 269:31334-31337.